Wide Ranks

LGVN

Longeveron Inc.

2.06

Top Statistics
Market Cap 30 M Forward PE -1.35 Revenue Growth 115.70 %
Current Ratio 4.18 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.30 Enterprise / Revenue 18.23 Price To Sales Trailing12 Months 24.87
Profitability
Profit Margins 0.00 % Operating Margins -747.86 %
Balance Sheet
Total Cash 12 M Total Cash Per Share 0.8620 Total Debt 1 M
Total Debt To Equity 11.72 Current Ratio 4.18 Book Value Per Share 2.69
All Measures
Short Ratio 203.00 % Message Board Id finmb_410711455 Shares Short Prior Month 749645
Return On Equity -1.42 City Miami Uuid 0810e7c7-ed9c-3408-947e-be0c34d084bb
Previous Close 2.00 First Trade Date Epoch Utc 1 B Book Value 2.69
Beta 0.3490 Total Debt 1 M Volume 169235
Price To Book 0.7672 Last Split Date 1 B Fifty Two Week Low 0.7710
Total Cash Per Share 0.8620 Total Revenue 1 M Shares Short Previous Month Date 1 B
Target Median Price 9.50 Max Age 86400 Recommendation Mean 2.00
Sand P52 Week Change 0.3133 Operating Margins -747.86 % Target Mean Price 8.50
Net Income To Common -27904000 Short Percent Of Float 0.1024 Implied Shares Outstanding 14 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 382940
Average Volume10days 382940 Total Cash 12 M Next Fiscal Year End 1 B
Revenue Per Share 0.3640 Held Percent Insiders 0.1070 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 2.00
Target Low Price 6.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.02
Open 2.05 Free Cashflow -10034000 State FL
Dividend Yield 0.00 % Return On Assets -0.6224 Time Zone Short Name EST
Trailing Eps -5.62 Day Low 1.98 Address1 Life Science & Technology Park
Shares Outstanding 13 M Price Hint 4 Target High Price 10.00
Website https://longeveron.com 52 Week Change -0.8949 Average Volume 519842
Forward Eps -1.53 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 392.30 % Last Split Factor 1:10 Regular Market Day High 2.09
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 11.72
Fifty Two Week High 23.90 Day High 2.09 Shares Short 1 M
Regular Market Open 2.05 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 18.23 Revenue Growth 115.70 % Shares Percent Shares Out 0.0889
Operating Cashflow -16205000 Currency USD Time Zone Full Name America/New_York
Market Cap 30 M Is_nasdaq_100 False Zip 33136
Quote Type EQUITY Industry Biotechnology Long Name Longeveron Inc.
Regular Market Day Low 1.98 Held Percent Institutions 0.0334 Current Price 2.06
Address2 Suite 520 1951 NW 7th Avenue Enterprise To Ebitda -1.30 Financial Currency USD
Current Ratio 4.18 Gross Margins 58.99 % Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country United States Float Shares 11 M
Two Hundred Day Average 2.53 Enterprise Value 22 M Price To Sales Trailing12 Months 24.87
Forward PE -1.35 Regular Market Volume 169235 Ebitda -17219000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.

The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.

It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome.

Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.